~~<i id='79165BEE58'><strike id='79165BEE58'><tt id='79165BEE58'><pre id='79165BEE58'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

knowledge

author：fashion 2025-09-03 15:23:45 - browse：536

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： ER docs worry over extreme heat as a 'mass casualty event'

focus

leisure time

Wikipedia

knowledge

hotspot

entertainment

ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

WSS

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

A strong 6.5

15 die by electrocution after transformer explodes in northern India

Why you get paid to donate plasma but not blood

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

The cancer drug shortage isn’t new — and neither are the solutions

entertainment

knowledge

focus

Continuity nursing helped my family in our darkest PICU moments

As demand for Covid shots wanes, Moderna seeks its next success

Continuity nursing helped my family in our darkest PICU moments

Medical records are filled with copy

BioMarin wins approval for gene therapy to treat hemophilia A

Malaria cases in Florida and Texas: Here’s what you need to know

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Biden administration sends mixed signals on US soldier who crossed into North Korea

State Dept. review finds Biden bears some blame for Afghanistan failures

Psychedelics group wrestles with new pharma identity

leisure time

At least 13 dead in Texas as scorching temps continue

State Dept. review finds Biden bears some blame for Afghanistan failures

A Theranos scientist

Flagship, Pfizer team up in deal worth up to $7 billion

Moonlake's readout produced a cash windfall. Risks remain

Moonlake's readout produced a cash windfall. Risks remain

Wikipedia

knowledge

hotspot

entertainment